The Parathyroid Hormone (PTH) Day in chronic kidney disease (CKD) - From Bench to Bedside
Chronic kidney disease (CKD) is often associated with mineral and bone disorders globally described as renal osteodystrophy (ROD), ranging from high-turnover bone diseases such as secondary hyperparathyroidism (SHPT), with its extreme and severe manifestation osteitis fibrosa, to low-turnover bone diseases such as osteomalacia and adynamic bone disease. Serum parathyroid hormone (PTH) is a recognized marker of bone remodeling in patients with renal osteodystrophy. However, identification of N-terminal truncated PTH fragments, oxidized PTH, and new forms of PTH that interfere with PTH assays may be responsible for the great variability of PTH values and the difficulties of implementing the recommendations of the Kidney Disease Improving Global Outcomes. This CME course is entirely dedicated to PTH. It is divided in fourth sessions, the two first are focused on basic science and the last two are more clinical oriented. The educational event is addressed to nephrologists and physicians interested by bone metabolism to get a timely update of the new and unexpected PTH actions.